STOCK TITAN

Abeona Therapeutics: TPG GP A reports 7% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Abeona Therapeutics Inc. (ABEO) is the issuer in a joint Schedule 13G ownership report by TPG GP A, LLC, James G. Coulter and Jon Winkelried. Each reports shared voting and dispositive power over 4,761,050 common shares, equal to 7.0% of the class.

The shares are held directly by TPG Ellodi (266,667) and Ellodi Pharmaceuticals, L.P. (4,494,383). TPG GP A may be deemed a beneficial owner through its relationship to the holders; Mr. Coulter and Mr. Winkelried disclaim beneficial ownership except to the extent of their pecuniary interests.

Beneficial ownership 4,761,050 shares Reported by each of the three reporting persons, with shared voting and dispositive power.
Ownership percentage 7.0% Percentage of the class reported by each reporting person.
Assumed shares outstanding 68,041,223 shares Denominator used to calculate the reported 7.0% ownership.
Shares outstanding 57,146,840 shares As of November 5, 2026.
Shares issued in asset purchase agreement 4,494,383 shares Issued in connection with the agreement entered into November 6, 2026.
Shares issued in private placement 6,400,000 shares Issued November 10, 2026.
TPG Ellodi direct holding 266,667 shares Common shares directly held by TPG Ellodi.
beneficial ownership financial
"amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared Voting Power 4,761,050"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 4,761,050"
pecuniary interest financial
"except to the extent of their pecuniary interest therein"
Agreement of Joint Filing regulatory
"pursuant to an Agreement of Joint Filing"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ABEO shares do TPG GP A, James G. Coulter and Jon Winkelried report?

The three reporting persons each report shared voting and dispositive power over 4,761,050 ABEO common shares, or 7.0% of the class.

What share count did the ABEO 13G use to calculate the reported percentage?

The 7.0% calculation assumes 68,041,223 shares outstanding: 57,146,840 shares outstanding as of November 5, 2026, 4,494,383 shares issued in connection with the November 6, 2026 asset purchase agreement, and 6,400,000 shares issued in a private placement on November 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





00289Y206

(CUSIP Number)
11/06/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage beneficial ownership set forth in response to Item 11 above assumes that there is a total of 68,041,223 shares of Common Stock ("Common Stock") outstanding, which is the sum of the (i) 57,146,840 shares of Common Stock outstanding as of November 5, 2026, as reported in the Quarterly Report on Form 10-Q filed by Abeona Therapeutics Inc. (the "Issuer") with the Securities and Exchange Commission (the "Commission") on November 9, 2026, (ii) 4,494,383 shares of Common Stock issued in connection with the Asset Purchase Agreement the Issuer entered into on November 6, 2026, and (iii) 6,400,000 shares of Common Stock issued in a private placement on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage beneficial ownership set forth in response to Item 11 above assumes that there is a total of 68,041,223 shares of Common Stock outstanding, which is the sum of the (i) 57,146,840 shares of Common Stock outstanding as of November 5, 2026, as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on November 9, 2026, (ii) 4,494,383 shares of Common Stock issued in connection with the Asset Purchase Agreement the Issuer entered into on November 6, 2026, and (iii) 6,400,000 shares of Common Stock issued in a private placement on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage beneficial ownership set forth in response to Item 11 above assumes that there is a total of 68,041,223 shares of Common Stock outstanding, which is the sum of the (i) 57,146,840 shares of Common Stock outstanding as of November 5, 2026, as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on November 9, 2026, (ii) 4,494,383 shares of Common Stock issued in connection with the Asset Purchase Agreement the Issuer entered into on November 6, 2026, and (iii) 6,400,000 shares of Common Stock issued in a private placement on November 10, 2026.


SCHEDULE 13G



TPG GP A, LLC
Signature:/s/ Matthew White
Name/Title:Matthew White / Vice President
Date:11/16/2026
COULTER, JAMES G
Signature:/s/ Gerald Neugebauer
Name/Title:Gerald Neugebauer on behalf of James G. Coulter (1)
Date:11/16/2026
WINKELRIED JON
Signature:/s/ Gerald Neugebauer
Name/Title:Gerald Neugebauer on behalf of Jon Winkelried (2)
Date:11/16/2026

Comments accompanying signature: (1) Gerald Neugebauer is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Coulter on February 7, 2024 (SEC File No. 001-41617). (2) Gerald Neugebauer is signing on behalf of Mr. Winkelried pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Winkelried on February 7, 2024 (SEC File No. 001-41617).
Exhibit Information

Exhibit 1 Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.* * Incorporated herein by reference to the Agreement of Joint Filing by TPG Group Holdings (SBS) Advisors, Inc., TPG GP A, LLC, TPG Advisors VII, Inc., TPG Advisors VI, Inc., TPG Advisors VI-AIV, Inc., TPG Asia Advisors VI, Inc., David Bonderman, James G. Coulter, Jon Winkelried and Karl Peterson dated as of January 18, 2022, which was previously filed with the Commission as Exhibit 1 to Amendment No. 4 to Schedule 13D filed by TPG GP A, LLC, David Bonderman, James G. Coulter and Jon Winkelried on January 18, 2022 with respect to the shares of common stock of Allogene Therapeutics, Inc.

Keep reading